Poly(oxy-1,2-ethanediyl), α-[(1,1,3,3-tetramethylbutyl)phenyl]-ω-hydroxy-

CAS9036-19-5
EC618-541-1

List details

Entry number 42
Scope
  • Endocrine disrupting properties (Article 57(f) - environment)
Latest application date 2019-07-04
Sunset date 2021-01-04

Related substances

By adding any of the following substances to your watchlist, you would be monitoring this regulatory record and all possible new regulatory records related to that substance.

  • Poly(oxy-1,2-ethanediyl), α-[(1,1,3,3-tetramethylbutyl)phenyl]-ω-hydroxy- (Octyl Phenol Ethoxylate * Poly(oxy-1,2-ethanediyl), .alpha.-[(1,1,3,3- tetramethylbutyl)phenyl]-.omega.-hydroxy- (2EO) * Polyethylene Glycol Octylphenyl Ether * POLYOXYETHYLENE MONOOCTYLPHENYL ETHER * Octylphenoxypoly(ethoxyethanol) * α-[(1,1,3,3-Tetramethylbutyl)phenyl]-ω-hydroxypoly(oxy-1,2-ethanediyl) * nonionic surfactant * ethoxylated octylphenol)
    CAS: 9036-19-5, EC: 618-541-1

Related regulatory records

Record history

The following timeline shows when we detected changes of this regulatory record (the date might slightly differ from the date of the actual change). Additions between versions are hightlighted in green color, red color shows data removed between versions.

This version
April 26, 2022
  • EC: 618-541-1
  • Entry number: 42*42
  • Remarks: By way of derogation from the date mentioned above under ‘latest application date’, 22 June 2022 for uses as follows: ─ for the research, development and production of medicinal products falling within the scope of Directive 2001/83/EC or medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746 of the European Parliament and of the Council (Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176)), in view of their use for the diagnosis, treatment or prevention of the coronavirus disease (COVID-19), ─ in medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, for the diagnosis, treatment or prevention of COVID-19. By way of derogation from the date mentioned above under ‘sunset date’, 22 December 2023 for uses as follows: ─ for the research, development and production of medicinal products falling within the scope of Directive 2001/83/EC or medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, in view of their use for the diagnosis, treatment or prevention of COVID-19, ─ in medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, for the diagnosis, treatment or prevention of COVID-19.
Dec. 16, 2021
  • Entry number: 4242*
  • Remarks: By way of derogation from the date mentioned above under ‘latest application date’, 22 June 2022 for uses as follows: ─ for the research, development and production of medicinal products falling within the scope of Directive 2001/83/EC or medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746 of the European Parliament and of the Council (Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176)), in view of their use for the diagnosis, treatment or prevention of the coronavirus disease (COVID-19), ─ in medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, for the diagnosis, treatment or prevention of COVID-19. By way of derogation from the date mentioned above under ‘sunset date’, 22 December 2023 for uses as follows: ─ for the research, development and production of medicinal products falling within the scope of Directive 2001/83/EC or medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, in view of their use for the diagnosis, treatment or prevention of COVID-19, ─ in medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, for the diagnosis, treatment or prevention of COVID-19.
June 22, 2021
  • Name: Polyethylene glycol mono(tert-octylph-enyl) ether9036-19-5Poly(oxy-1,2-ethanediyl), α-[(1,1,3,3-tetramethylbutyl)phenyl]-ω-hydroxy-
  • EC: 618-541-1
Add the related substance to your watchlist to monitor this regulatory record.